This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2021 Nov 16;73(10):1857-1859.

doi: 10.1093/cid/ciab220.

Remdesivir: An Antiviral Still Seeking a Raison d'Être

Nathan W Cummins¹

Affiliations

PMID: 33749746
PMCID: PMC8083721
DOI: 10.1093/cid/ciab220

Editorial

Remdesivir: An Antiviral Still Seeking a Raison d'Être

Nathan W Cummins. Clin Infect Dis. 2021.

. 2021 Nov 16;73(10):1857-1859.

doi: 10.1093/cid/ciab220.

Author

Nathan W Cummins¹

Affiliation

¹ Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, USA.

PMID: 33749746
PMCID: PMC8083721
DOI: 10.1093/cid/ciab220

No abstract available

Keywords: COVID-19; Ebola virus disease; remdesivir.

PubMed Disclaimer

Comment on

PREVAIL IV: A Randomized, Double-Blind, 2-Phase, Phase 2 Trial of Remdesivir vs Placebo for Reduction of Ebola Virus RNA in the Semen of Male Survivors.
Higgs ES, Gayedyu-Dennis D, Fischer Ii WA, Nason M, Reilly C, Beavogui AH, Aboulhab J, Nordwall J, Lobbo P, Wachekwa I, Cao H, Cihlar T, Hensley L, Lane HC. Higgs ES, et al. Clin Infect Dis. 2021 Nov 16;73(10):1849-1856. doi: 10.1093/cid/ciab215. Clin Infect Dis. 2021. PMID: 33709142 Free PMC article. Clinical Trial.

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

Grants and funding

Mayo Clinic Foundation

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations